J&J: terminates collaboration with Bavarian Nordic
(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceutical Companies today announced that it has terminated its collaboration and licensing agreements with Bavarian Nordic for the MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) technology for the development of potential vaccines against hepatitis B virus and human papillomavirus.
However, Janssen remains committed to its strong collaboration with Bavarian Nordic in the prevention and cure of infectious diseases - with ongoing collaborations on HIV and Ebola.
Janssen will continue to prioritise hepatitis B using alternative investigational vaccine platforms and therapies within its broad portfolio and has several ongoing studies.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
However, Janssen remains committed to its strong collaboration with Bavarian Nordic in the prevention and cure of infectious diseases - with ongoing collaborations on HIV and Ebola.
Janssen will continue to prioritise hepatitis B using alternative investigational vaccine platforms and therapies within its broad portfolio and has several ongoing studies.
Copyright (c) 2022 CercleFinance.com. All rights reserved.